NovoCure Ltd. Hits Day Low of $13.89 Amid Price Pressure

NovoCure Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced significant volatility today, with the stock hitting an intraday low of USD 13.89. The company’s performance has been notably challenging, as evidenced by a sharp decline of 20.0% on June 18, 2026. In terms of performance metrics, NovoCure has underperformed relative to the S&P 500 across various time frames. Over the past year, the stock has generated a return of just 2.41%, significantly trailing the S&P 500's impressive 24.03% return. The one-day performance reflects a stark contrast to the broader market, which saw a modest gain of 1.08%. Financially, NovoCure's position raises concerns, with a debt-equity ratio of -0.74 and a return on equity of -40.01%. The company's cash and equivalents stand at USD 899.32 million, indicating liquidity challenges. Overall, the stock's recent activity underscores a period of notable difficulty for NovoCure, as it navigates a complex market landscape.